Who
Kristen Cunningham
Chief Sales Officer
Company insider
Files Form 4 as: Chief Sales Officer, Lifevantage.
In numbers
- Trades disclosed
- 65
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $111K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Aug 2022
- Last trade
- 7 Oct 2026
- Last filed
- 9 Oct 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Oct 2026filed 9 Oct 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code A | —32,850 at $0.00 | filing |
| 7 Oct 2026filed 9 Oct 2026 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,275 at $0.00 | filing |
| 1 Oct 2026filed 5 Oct 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $3,975637 at $6.24 | filing |
| 14 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Sold | $55K8,901 at $6.18 | filing |
| 14 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Sold | $55K8,901 at $6.18 | filing |
| 11 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Sold | $641100 at $6.41 | filing |
| 11 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Sold | $641100 at $6.41 | filing |
| 10 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $14K2,254 at $6.37 | filing |
| 10 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $14K2,254 at $6.37 | filing |
| 1 Jul 2026filed 6 Jul 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $11K1,717 at $6.25 | filing |
| 1 Jul 2026filed 6 Jul 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $11K1,717 at $6.25 | filing |
| 1 Apr 2026filed 3 Apr 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $8,0981,928 at $4.20 | filing |
| 1 Apr 2026filed 3 Apr 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $8,0981,928 at $4.20 | filing |
| 1 Jan 2026filed 5 Jan 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $12K1,926 at $6.16 | filing |
| 1 Jan 2026filed 5 Jan 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $12K1,926 at $6.16 | filing |
| 1 Oct 2025filed 3 Oct 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $16K1,720 at $9.56 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,752 at $0.00 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code M | —26,150 at $0.00 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code M | —17,752 at $0.00 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code M | —26,150 at $0.00 | filing |
News
Kristen Cunningham Sells 8,901 Shares of Lifevantage (NASDAQ:LFVN) Stockthemarketsdaily.com · 15 Sep 2026LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LFVN · manilatimes.net · 12 Oct 2026
1 headline in the last 90 days name Kristen Cunningham; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.